Two things happened to Moderna this month, and both are real. On August 5 the FDA approved mFLUSIVA (mRNA-1010) for adults 50 and older — the first mRNA-based seasonal influenza vaccine, and the company's fourth approved US product, with full approval in ages 50 to 64 and accelerated approval in 65-plus contingent on a confirmatory trial. On August 19 Moderna and Merck announced that the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met both its recurrence-free survival and distant metastasis-free survival endpoints in completely resected Stage IIB–IV melanoma. It is the first positive Phase 3 for an individualised neoantigen therapy.
The stock closed at $62.96 on August 18 and traded at $132.72 at midday on August 19. Across 398 million diluted shares that is about $27.8 billion of market value added in a morning, taking the company from roughly $25.1 billion to $52.8 billion.
That number has three denominators, and they are the reason this piece exists.
What $27.8 billion is a multiple of
| The morning's gain, against | Amount | Multiple |
|---|---|---|
| Trailing twelve-month revenue | $2.23B | 12.5x |
| Free cash flow burned since 2023 Q1 | $11.20B | 2.5x |
| Peak COVID-era annual revenue (FY2022) | $19.26B | 1.44x |
Read the middle row twice. The market added two and a half times everything Moderna has burned in fourteen quarters, in about three hours. The burn is not a rounding error either — $11.2 billion of negative free cash flow, every quarter of it filed, from a company that has been cutting hard the whole time.
And read the bottom row. The one-day gain is worth more than the entire revenue of 2022, the year the COVID vaccine was at its absolute peak and Moderna booked $19.3 billion. The market is not repricing the business it has. It is pricing one it does not have yet.
The business it has
Here is what the June quarter actually reported, from the 2026 Q2 capture:
- Revenue $145 million, against $142 million in the June 2025 quarter — growth of 2.1%.
- Diluted loss per share $(1.97), roughly a $784 million net loss.
- Operating cash flow $(526) million, capex $37 million, so free cash flow of $(563) million.
That last pair is the Rule of 40 input, and it produces a number the scale is not built for: 2.1% revenue growth plus an FCF margin of −388% is a Rule of 40 score of roughly −385. On a trailing basis it is less absurd and still bad — $2.23 billion of revenue against $1.24 billion of cash burn is a −56% FCF margin.
The trajectory is the one genuinely encouraging line in the filings. Quarterly burn has gone from $(1.46) billion in 2024 Q2 to $(563) million in 2026 Q2 — a 61% reduction — and the September quarters, which carry the respiratory selling season, are no longer the only ones that matter. But cutting burn by two thirds does not make $145 million a quarter into a business. It buys quarters.
What the pipeline has to earn
The obvious next step is to size the two programmes and show the gap. This is where most analysis quietly invents a number, and we are not going to: neither Moderna nor Merck has published a peak-sales estimate for intismeran autogene, the INTerpath-001 data has not been presented yet — the companies said only that they will present at an upcoming medical meeting and engage with regulators on filings — and mFLUSIVA has been approved for weeks, not sold for a season.
What can be done honestly is to invert it. The multiple is ours, not anyone's guidance, and the arithmetic is one division:
| If the market pays… | …the $27.8B implies annual revenue of | Against TTM revenue of $2.23B |
|---|---|---|
| 8x revenue | $3.47B | 1.6x |
| 5x revenue | $5.55B | 2.5x |
| 3x revenue | $9.25B | 4.2x |
At five times revenue — unremarkable for approved pharma with patent life — Wednesday morning priced in $5.6 billion a year that does not exist today, about two and a half times the company's entire trailing revenue and roughly what Moderna booked across all of 2023 and 2024 combined. At three times, it priced in $9.25 billion, close to half the COVID peak.
None of those is impossible. A first-in-class adjuvant melanoma therapy partnered with the company that owns KEYTRUDA, plus the first mRNA flu vaccine in a market that vaccinates on a calendar, is a defensible bull case. The point is the size of what has to arrive, and that it has to arrive against a revenue line currently growing 2%.
There is no r40 forward model for MRNA, so this piece has nothing to reconcile against — which is itself the honest statement. A model would need a peak-sales assumption for two products with no disclosed one, and that assumption would be the entire answer.
What to watch
- The INTerpath-001 data itself. Topline says the endpoints were met; it does not say by how much. The hazard ratios and the absolute recurrence-free survival separation, when presented, are what turn a binary into a number.
- Whether mFLUSIVA gets an ACIP recommendation, and how broad. FDA approval clears the shelf; the CDC recommendation is what determines whether it is bought at scale for the 2026–27 season.
- The September quarter's revenue line. Q3 is the respiratory selling season — $1.02 billion in 2025 Q3 against $1.86 billion in 2024 Q3. Whether that decline continues is a fact about the business that no pipeline news changes.
- Cash burn against the cash balance. $1.72 billion of cash, cash equivalents and restricted cash at June 30 against a $563 million quarterly burn is the clock this company is actually running on, and every quarter of improvement extends it.
Moderna's quarterly revenue, diluted EPS, operating cash flow, capex and cost of sales are from its SEC filings via XBRL company facts (CIK 0001682852), with quarterly figures derived from year-to-date filings where the company reports cumulatively; free cash flow is operating cash flow less purchases of property and equipment, our arithmetic on filed figures. Full-year revenue of $19.263B (2022), $6.848B (2023), $3.236B (2024) and $1.944B (2025) is filed. The June-quarter cash balance of $1.72B is from the 2026 Q2 10-Q filed July 31, 2026. Share count is the 398 million weighted-average diluted shares from that filing, per this site's convention of using the diluted count. The $62.96 August 18 close and the $132.72 August 19 midday price are market quotes as of those moments and will not be the numbers you see today; every market-value figure here is derived from them. The mFLUSIVA approval terms and the INTerpath-001 endpoints are from the companies' own August 2026 announcements. The revenue multiples in the last table are ours, chosen to bracket the range, and are not anyone's guidance or estimate — no peak-sales figure for either programme has been published by Moderna or Merck.
